Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 3

1(33.3%)

N/A

1(33.3%)

3Total

Phase 2(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials

NCT07038356Phase 3Recruiting

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

Role: lead

NCT05027529Not ApplicableCompleted

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

Role: lead

NCT04049045Phase 2Completed

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Role: lead

All 3 trials loaded